The latest medical insurance price of regorafenib in 2024

Regorafenib (Regorafenib) is an oral multi-target inhibitor that is widely used to treat malignant tumors such as advanced colorectal cancer, gastrointestinal stromal tumor (GIST), and hepatocellular carcinoma. It belongs to the category of targeted drugs, and its mechanism of action is to prevent the growth and spread of tumors by inhibiting multiple key signaling pathways in and around tumor cells.

Regorafenib has been officially launched in China and has been successfully included in the medical insurance system, which means that patients can easily purchase this drug in China at a price of about four to five thousand yuan. For specific price information and medical insurance reimbursement ratios, it is recommended that you consult the local hospital pharmacy to obtain the most accurate information.

In foreign markets, Regorafenib (Regofenib) has two types: original drugs and generic drugs. Among them, the original drugs are mainly Turkish versions, and the price is relatively low, only costing more than one thousand yuan. At the same time, generic drugs are also an affordable option. Laos, India and Bangladesh produce generic drugs, with prices ranging from a few hundred yuan to more than a thousand yuan. It is worth noting that the main pharmaceutical ingredients of original drugs and generic drugs are the same.

The mechanism of action of regorafenib includes inhibiting tumor angiogenesis, inhibiting tumor cell proliferation and promoting apoptosis, and inhibiting the metastasis and invasion ability of tumor cells. These effects enable Regorafenib to interfere with the growth process of tumors, thereby prolonging patients' survival time and improving their quality of life.

In clinical practice,regorafenib is usually used as a single agent or in combination with other drugs. For patients whose tumors have progressed despite other treatments, regorafenib may become a first-line or later-line treatment option. Studies have shown that regorafenibcan significantly extend the survival time of patients with advanced colorectal cancer and GIST compared with placebo.

Although Regorafenib has shown certain efficacy in treatment, there are also some adverse reactions, including but not limited to fatigue, hypertension, hand-foot syndrome, etc. Therefore, before using regorafenib, doctors need to conduct a thorough evaluation of the patient's medical condition and carefully weigh the risks and benefits of treatment.